nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PPARG—type 2 diabetes mellitus	0.187	0.703	CbGaD
Mesalazine—PPARG—Glipizide—type 2 diabetes mellitus	0.0954	0.205	CbGbCtD
Mesalazine—PPARG—Repaglinide—type 2 diabetes mellitus	0.0834	0.179	CbGbCtD
Mesalazine—PTGS2—type 2 diabetes mellitus	0.0787	0.297	CbGaD
Mesalazine—PPARG—Pioglitazone—type 2 diabetes mellitus	0.0754	0.162	CbGbCtD
Mesalazine—PPARG—Rosiglitazone—type 2 diabetes mellitus	0.0696	0.15	CbGbCtD
Mesalazine—PPARG—Nateglinide—type 2 diabetes mellitus	0.0571	0.123	CbGbCtD
Mesalazine—PTGS1—Chlorpropamide—type 2 diabetes mellitus	0.019	0.0409	CbGbCtD
Mesalazine—PTGS1—Pioglitazone—type 2 diabetes mellitus	0.019	0.0409	CbGbCtD
Mesalazine—PTGS1—Rosiglitazone—type 2 diabetes mellitus	0.0175	0.0377	CbGbCtD
Mesalazine—PTGS1—Nateglinide—type 2 diabetes mellitus	0.0144	0.031	CbGbCtD
Mesalazine—PTGS1—Irbesartan—type 2 diabetes mellitus	0.0138	0.0297	CbGbCtD
Mesalazine—PPARG—brown adipose tissue—type 2 diabetes mellitus	0.00329	0.0924	CbGeAlD
Mesalazine—PPARG—leg—type 2 diabetes mellitus	0.00264	0.0744	CbGeAlD
Mesalazine—PPARG—hindlimb—type 2 diabetes mellitus	0.00236	0.0664	CbGeAlD
Mesalazine—MPO—artery—type 2 diabetes mellitus	0.00163	0.0459	CbGeAlD
Mesalazine—PPARG—artery—type 2 diabetes mellitus	0.00145	0.0407	CbGeAlD
Mesalazine—MPO—endothelium—type 2 diabetes mellitus	0.00138	0.0387	CbGeAlD
Mesalazine—PTGS2—leg—type 2 diabetes mellitus	0.00135	0.038	CbGeAlD
Mesalazine—PPARG—endothelium—type 2 diabetes mellitus	0.00122	0.0344	CbGeAlD
Mesalazine—PTGS2—hindlimb—type 2 diabetes mellitus	0.00121	0.0339	CbGeAlD
Mesalazine—CHUK—cardiovascular system—type 2 diabetes mellitus	0.00119	0.0334	CbGeAlD
Mesalazine—CHUK—adipose tissue—type 2 diabetes mellitus	0.00105	0.0295	CbGeAlD
Mesalazine—ALOX5—islet of Langerhans—type 2 diabetes mellitus	0.000926	0.026	CbGeAlD
Mesalazine—IKBKB—cardiovascular system—type 2 diabetes mellitus	0.000808	0.0227	CbGeAlD
Mesalazine—PTGS1—artery—type 2 diabetes mellitus	0.000774	0.0218	CbGeAlD
Mesalazine—IKBKB—cortex of kidney—type 2 diabetes mellitus	0.00077	0.0217	CbGeAlD
Mesalazine—PTGS2—artery—type 2 diabetes mellitus	0.000739	0.0208	CbGeAlD
Mesalazine—CHUK—liver—type 2 diabetes mellitus	0.000735	0.0207	CbGeAlD
Mesalazine—IKBKB—adipose tissue—type 2 diabetes mellitus	0.000713	0.02	CbGeAlD
Mesalazine—PPARG—islet of Langerhans—type 2 diabetes mellitus	0.000695	0.0196	CbGeAlD
Mesalazine—ALOX5—cardiovascular system—type 2 diabetes mellitus	0.00067	0.0188	CbGeAlD
Mesalazine—PTGS1—endothelium—type 2 diabetes mellitus	0.000653	0.0184	CbGeAlD
Mesalazine—ALOX5—pancreas—type 2 diabetes mellitus	0.000651	0.0183	CbGeAlD
Mesalazine—PTGS2—endothelium—type 2 diabetes mellitus	0.000625	0.0176	CbGeAlD
Mesalazine—ALOX5—adipose tissue—type 2 diabetes mellitus	0.000591	0.0166	CbGeAlD
Mesalazine—MPO—cardiovascular system—type 2 diabetes mellitus	0.000567	0.0159	CbGeAlD
Mesalazine—MPO—kidney—type 2 diabetes mellitus	0.000554	0.0156	CbGeAlD
Mesalazine—MPO—pancreas—type 2 diabetes mellitus	0.000551	0.0155	CbGeAlD
Mesalazine—PPARG—cardiovascular system—type 2 diabetes mellitus	0.000503	0.0141	CbGeAlD
Mesalazine—IKBKB—liver—type 2 diabetes mellitus	0.0005	0.0141	CbGeAlD
Mesalazine—PPARG—kidney—type 2 diabetes mellitus	0.000492	0.0138	CbGeAlD
Mesalazine—PPARG—pancreas—type 2 diabetes mellitus	0.000489	0.0137	CbGeAlD
Mesalazine—PPARG—adipose tissue—type 2 diabetes mellitus	0.000443	0.0125	CbGeAlD
Mesalazine—ALOX5—liver—type 2 diabetes mellitus	0.000414	0.0117	CbGeAlD
Mesalazine—Droxidopa—ADRB3—type 2 diabetes mellitus	0.000388	0.18	CrCbGaD
Mesalazine—PTGS2—islet of Langerhans—type 2 diabetes mellitus	0.000355	0.00999	CbGeAlD
Mesalazine—MPO—liver—type 2 diabetes mellitus	0.00035	0.00986	CbGeAlD
Mesalazine—Olsalazine—PPARG—type 2 diabetes mellitus	0.000337	0.156	CrCbGaD
Mesalazine—PPARG—liver—type 2 diabetes mellitus	0.000311	0.00875	CbGeAlD
Mesalazine—Methyldopa—ADRA2A—type 2 diabetes mellitus	0.000282	0.131	CrCbGaD
Mesalazine—PTGS1—cardiovascular system—type 2 diabetes mellitus	0.000269	0.00756	CbGeAlD
Mesalazine—PTGS1—kidney—type 2 diabetes mellitus	0.000263	0.0074	CbGeAlD
Mesalazine—PTGS2—cardiovascular system—type 2 diabetes mellitus	0.000257	0.00723	CbGeAlD
Mesalazine—PTGS2—kidney—type 2 diabetes mellitus	0.000251	0.00707	CbGeAlD
Mesalazine—PTGS2—pancreas—type 2 diabetes mellitus	0.00025	0.00703	CbGeAlD
Mesalazine—PTGS1—adipose tissue—type 2 diabetes mellitus	0.000237	0.00667	CbGeAlD
Mesalazine—PTGS2—adipose tissue—type 2 diabetes mellitus	0.000227	0.00637	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—type 2 diabetes mellitus	0.000208	0.0963	CrCbGaD
Mesalazine—Droxidopa—ADRA2A—type 2 diabetes mellitus	0.000176	0.0815	CrCbGaD
Mesalazine—PTGS2—liver—type 2 diabetes mellitus	0.000159	0.00447	CbGeAlD
Mesalazine—Olsalazine—PTGS2—type 2 diabetes mellitus	0.000142	0.066	CrCbGaD
Mesalazine—Diflunisal—PTGS2—type 2 diabetes mellitus	0.000134	0.0621	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—type 2 diabetes mellitus	0.000134	0.0621	CrCbGaD
Mesalazine—Diflunisal—ALB—type 2 diabetes mellitus	0.000119	0.0553	CrCbGaD
Mesalazine—Dopamine—CYP1A2—type 2 diabetes mellitus	9.56e-05	0.0443	CrCbGaD
Mesalazine—Salicylic acid—PTGS2—type 2 diabetes mellitus	7.44e-05	0.0345	CrCbGaD
Mesalazine—Salicylic acid—ALB—type 2 diabetes mellitus	6.63e-05	0.0308	CrCbGaD
Mesalazine—Anxiety—Irbesartan—type 2 diabetes mellitus	3.87e-05	0.000278	CcSEcCtD
Mesalazine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	3.87e-05	0.000278	CcSEcCtD
Mesalazine—Nervous system disorder—Metformin—type 2 diabetes mellitus	3.87e-05	0.000278	CcSEcCtD
Mesalazine—Thrombocytopenia—Metformin—type 2 diabetes mellitus	3.86e-05	0.000277	CcSEcCtD
Mesalazine—Dyspnoea—Valsartan—type 2 diabetes mellitus	3.86e-05	0.000277	CcSEcCtD
Mesalazine—Vertigo—Losartan—type 2 diabetes mellitus	3.85e-05	0.000277	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	3.85e-05	0.000277	CcSEcCtD
Mesalazine—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	3.85e-05	0.000277	CcSEcCtD
Mesalazine—Somnolence—Valsartan—type 2 diabetes mellitus	3.85e-05	0.000276	CcSEcCtD
Mesalazine—Syncope—Losartan—type 2 diabetes mellitus	3.85e-05	0.000276	CcSEcCtD
Mesalazine—Paraesthesia—Orlistat—type 2 diabetes mellitus	3.84e-05	0.000276	CcSEcCtD
Mesalazine—Leukopenia—Losartan—type 2 diabetes mellitus	3.84e-05	0.000276	CcSEcCtD
Mesalazine—Discomfort—Irbesartan—type 2 diabetes mellitus	3.83e-05	0.000275	CcSEcCtD
Mesalazine—Skin disorder—Metformin—type 2 diabetes mellitus	3.83e-05	0.000275	CcSEcCtD
Mesalazine—Immune system disorder—Ramipril—type 2 diabetes mellitus	3.82e-05	0.000274	CcSEcCtD
Mesalazine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	3.81e-05	0.000274	CcSEcCtD
Mesalazine—Dyspepsia—Valsartan—type 2 diabetes mellitus	3.81e-05	0.000274	CcSEcCtD
Mesalazine—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	3.81e-05	0.000273	CcSEcCtD
Mesalazine—Dizziness—Bromocriptine—type 2 diabetes mellitus	3.8e-05	0.000272	CcSEcCtD
Mesalazine—Dry mouth—Irbesartan—type 2 diabetes mellitus	3.8e-05	0.000272	CcSEcCtD
Mesalazine—Palpitations—Losartan—type 2 diabetes mellitus	3.79e-05	0.000272	CcSEcCtD
Mesalazine—Nausea—Glimepiride—type 2 diabetes mellitus	3.78e-05	0.000271	CcSEcCtD
Mesalazine—Loss of consciousness—Losartan—type 2 diabetes mellitus	3.77e-05	0.000271	CcSEcCtD
Mesalazine—Nausea—Sitagliptin—type 2 diabetes mellitus	3.77e-05	0.00027	CcSEcCtD
Mesalazine—Dyspepsia—Orlistat—type 2 diabetes mellitus	3.77e-05	0.00027	CcSEcCtD
Mesalazine—Asthenia—Glyburide—type 2 diabetes mellitus	3.77e-05	0.00027	CcSEcCtD
Mesalazine—Decreased appetite—Valsartan—type 2 diabetes mellitus	3.76e-05	0.00027	CcSEcCtD
Mesalazine—Anorexia—Metformin—type 2 diabetes mellitus	3.76e-05	0.00027	CcSEcCtD
Mesalazine—Cough—Losartan—type 2 diabetes mellitus	3.74e-05	0.000269	CcSEcCtD
Mesalazine—Urticaria—Gliclazide—type 2 diabetes mellitus	3.74e-05	0.000269	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	3.74e-05	0.000268	CcSEcCtD
Mesalazine—Alopecia—Ramipril—type 2 diabetes mellitus	3.73e-05	0.000268	CcSEcCtD
Mesalazine—Fatigue—Valsartan—type 2 diabetes mellitus	3.73e-05	0.000268	CcSEcCtD
Mesalazine—Abdominal pain—Gliclazide—type 2 diabetes mellitus	3.73e-05	0.000267	CcSEcCtD
Mesalazine—Body temperature increased—Gliclazide—type 2 diabetes mellitus	3.73e-05	0.000267	CcSEcCtD
Mesalazine—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	3.72e-05	0.000267	CcSEcCtD
Mesalazine—Oedema—Irbesartan—type 2 diabetes mellitus	3.72e-05	0.000267	CcSEcCtD
Mesalazine—Decreased appetite—Orlistat—type 2 diabetes mellitus	3.72e-05	0.000267	CcSEcCtD
Mesalazine—Pruritus—Glyburide—type 2 diabetes mellitus	3.71e-05	0.000267	CcSEcCtD
Mesalazine—Mental disorder—Ramipril—type 2 diabetes mellitus	3.7e-05	0.000266	CcSEcCtD
Mesalazine—Constipation—Valsartan—type 2 diabetes mellitus	3.7e-05	0.000266	CcSEcCtD
Mesalazine—Infection—Irbesartan—type 2 diabetes mellitus	3.7e-05	0.000265	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	3.69e-05	0.000265	CcSEcCtD
Mesalazine—Fatigue—Orlistat—type 2 diabetes mellitus	3.69e-05	0.000265	CcSEcCtD
Mesalazine—Hypotension—Metformin—type 2 diabetes mellitus	3.68e-05	0.000264	CcSEcCtD
Mesalazine—Erythema—Ramipril—type 2 diabetes mellitus	3.68e-05	0.000264	CcSEcCtD
Mesalazine—Shock—Irbesartan—type 2 diabetes mellitus	3.66e-05	0.000263	CcSEcCtD
Mesalazine—Pain—Orlistat—type 2 diabetes mellitus	3.66e-05	0.000263	CcSEcCtD
Mesalazine—Arthralgia—Losartan—type 2 diabetes mellitus	3.65e-05	0.000262	CcSEcCtD
Mesalazine—Chest pain—Losartan—type 2 diabetes mellitus	3.65e-05	0.000262	CcSEcCtD
Mesalazine—Myalgia—Losartan—type 2 diabetes mellitus	3.65e-05	0.000262	CcSEcCtD
Mesalazine—Vomiting—Bromocriptine—type 2 diabetes mellitus	3.65e-05	0.000262	CcSEcCtD
Mesalazine—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	3.65e-05	0.000262	CcSEcCtD
Mesalazine—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	3.64e-05	0.000261	CcSEcCtD
Mesalazine—Anxiety—Losartan—type 2 diabetes mellitus	3.64e-05	0.000261	CcSEcCtD
Mesalazine—Tachycardia—Irbesartan—type 2 diabetes mellitus	3.63e-05	0.000261	CcSEcCtD
Mesalazine—Rash—Bromocriptine—type 2 diabetes mellitus	3.62e-05	0.00026	CcSEcCtD
Mesalazine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	3.62e-05	0.00026	CcSEcCtD
Mesalazine—Skin disorder—Irbesartan—type 2 diabetes mellitus	3.61e-05	0.000259	CcSEcCtD
Mesalazine—Tension—Ramipril—type 2 diabetes mellitus	3.61e-05	0.000259	CcSEcCtD
Mesalazine—Discomfort—Losartan—type 2 diabetes mellitus	3.61e-05	0.000259	CcSEcCtD
Mesalazine—Dysgeusia—Ramipril—type 2 diabetes mellitus	3.6e-05	0.000259	CcSEcCtD
Mesalazine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	3.6e-05	0.000258	CcSEcCtD
Mesalazine—Headache—Bromocriptine—type 2 diabetes mellitus	3.6e-05	0.000258	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	3.59e-05	0.000258	CcSEcCtD
Mesalazine—Diarrhoea—Glyburide—type 2 diabetes mellitus	3.59e-05	0.000258	CcSEcCtD
Mesalazine—Nervousness—Ramipril—type 2 diabetes mellitus	3.57e-05	0.000256	CcSEcCtD
Mesalazine—Dry mouth—Losartan—type 2 diabetes mellitus	3.57e-05	0.000256	CcSEcCtD
Mesalazine—Anorexia—Irbesartan—type 2 diabetes mellitus	3.55e-05	0.000255	CcSEcCtD
Mesalazine—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	3.54e-05	0.000254	CcSEcCtD
Mesalazine—Paraesthesia—Metformin—type 2 diabetes mellitus	3.54e-05	0.000254	CcSEcCtD
Mesalazine—Muscle spasms—Ramipril—type 2 diabetes mellitus	3.54e-05	0.000254	CcSEcCtD
Mesalazine—Confusional state—Losartan—type 2 diabetes mellitus	3.53e-05	0.000253	CcSEcCtD
Mesalazine—Feeling abnormal—Orlistat—type 2 diabetes mellitus	3.53e-05	0.000253	CcSEcCtD
Mesalazine—Dyspnoea—Metformin—type 2 diabetes mellitus	3.51e-05	0.000252	CcSEcCtD
Mesalazine—Somnolence—Metformin—type 2 diabetes mellitus	3.5e-05	0.000252	CcSEcCtD
Mesalazine—Anaphylactic shock—Losartan—type 2 diabetes mellitus	3.5e-05	0.000251	CcSEcCtD
Mesalazine—Oedema—Losartan—type 2 diabetes mellitus	3.5e-05	0.000251	CcSEcCtD
Mesalazine—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	3.5e-05	0.000251	CcSEcCtD
Mesalazine—Infection—Losartan—type 2 diabetes mellitus	3.48e-05	0.00025	CcSEcCtD
Mesalazine—Hypotension—Irbesartan—type 2 diabetes mellitus	3.48e-05	0.00025	CcSEcCtD
Mesalazine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	3.47e-05	0.000249	CcSEcCtD
Mesalazine—Dyspepsia—Metformin—type 2 diabetes mellitus	3.47e-05	0.000249	CcSEcCtD
Mesalazine—Tremor—Ramipril—type 2 diabetes mellitus	3.45e-05	0.000247	CcSEcCtD
Mesalazine—Shock—Losartan—type 2 diabetes mellitus	3.44e-05	0.000247	CcSEcCtD
Mesalazine—Urticaria—Valsartan—type 2 diabetes mellitus	3.44e-05	0.000247	CcSEcCtD
Mesalazine—Nervous system disorder—Losartan—type 2 diabetes mellitus	3.43e-05	0.000246	CcSEcCtD
Mesalazine—Thrombocytopenia—Losartan—type 2 diabetes mellitus	3.43e-05	0.000246	CcSEcCtD
Mesalazine—Decreased appetite—Metformin—type 2 diabetes mellitus	3.43e-05	0.000246	CcSEcCtD
Mesalazine—Abdominal pain—Valsartan—type 2 diabetes mellitus	3.42e-05	0.000246	CcSEcCtD
Mesalazine—Tachycardia—Losartan—type 2 diabetes mellitus	3.42e-05	0.000245	CcSEcCtD
Mesalazine—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	3.41e-05	0.000245	CcSEcCtD
Mesalazine—Nausea—Bromocriptine—type 2 diabetes mellitus	3.41e-05	0.000245	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	3.4e-05	0.000244	CcSEcCtD
Mesalazine—Fatigue—Metformin—type 2 diabetes mellitus	3.4e-05	0.000244	CcSEcCtD
Mesalazine—Urticaria—Orlistat—type 2 diabetes mellitus	3.4e-05	0.000244	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	3.39e-05	0.000243	CcSEcCtD
Mesalazine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	3.38e-05	0.000243	CcSEcCtD
Mesalazine—Abdominal pain—Orlistat—type 2 diabetes mellitus	3.38e-05	0.000243	CcSEcCtD
Mesalazine—Body temperature increased—Orlistat—type 2 diabetes mellitus	3.38e-05	0.000243	CcSEcCtD
Mesalazine—Asthenia—Gliclazide—type 2 diabetes mellitus	3.38e-05	0.000243	CcSEcCtD
Mesalazine—Constipation—Metformin—type 2 diabetes mellitus	3.37e-05	0.000242	CcSEcCtD
Mesalazine—Angioedema—Ramipril—type 2 diabetes mellitus	3.36e-05	0.000241	CcSEcCtD
Mesalazine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	3.34e-05	0.00024	CcSEcCtD
Mesalazine—Anorexia—Losartan—type 2 diabetes mellitus	3.34e-05	0.00024	CcSEcCtD
Mesalazine—Vomiting—Glyburide—type 2 diabetes mellitus	3.34e-05	0.00024	CcSEcCtD
Mesalazine—Pruritus—Gliclazide—type 2 diabetes mellitus	3.33e-05	0.000239	CcSEcCtD
Mesalazine—Malaise—Ramipril—type 2 diabetes mellitus	3.32e-05	0.000238	CcSEcCtD
Mesalazine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	3.32e-05	0.000238	CcSEcCtD
Mesalazine—Rash—Glyburide—type 2 diabetes mellitus	3.31e-05	0.000238	CcSEcCtD
Mesalazine—Somnolence—Irbesartan—type 2 diabetes mellitus	3.31e-05	0.000237	CcSEcCtD
Mesalazine—Dermatitis—Glyburide—type 2 diabetes mellitus	3.31e-05	0.000237	CcSEcCtD
Mesalazine—Vertigo—Ramipril—type 2 diabetes mellitus	3.31e-05	0.000237	CcSEcCtD
Mesalazine—Syncope—Ramipril—type 2 diabetes mellitus	3.3e-05	0.000237	CcSEcCtD
Mesalazine—Leukopenia—Ramipril—type 2 diabetes mellitus	3.29e-05	0.000236	CcSEcCtD
Mesalazine—Headache—Glyburide—type 2 diabetes mellitus	3.29e-05	0.000236	CcSEcCtD
Mesalazine—Dyspepsia—Irbesartan—type 2 diabetes mellitus	3.28e-05	0.000235	CcSEcCtD
Mesalazine—Hypotension—Losartan—type 2 diabetes mellitus	3.27e-05	0.000235	CcSEcCtD
Mesalazine—Palpitations—Ramipril—type 2 diabetes mellitus	3.25e-05	0.000233	CcSEcCtD
Mesalazine—Feeling abnormal—Metformin—type 2 diabetes mellitus	3.25e-05	0.000233	CcSEcCtD
Mesalazine—Decreased appetite—Irbesartan—type 2 diabetes mellitus	3.23e-05	0.000232	CcSEcCtD
Mesalazine—Loss of consciousness—Ramipril—type 2 diabetes mellitus	3.23e-05	0.000232	CcSEcCtD
Mesalazine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	3.22e-05	0.000231	CcSEcCtD
Mesalazine—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	3.22e-05	0.000231	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	3.21e-05	0.000231	CcSEcCtD
Mesalazine—Cough—Ramipril—type 2 diabetes mellitus	3.21e-05	0.00023	CcSEcCtD
Mesalazine—Fatigue—Irbesartan—type 2 diabetes mellitus	3.21e-05	0.00023	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	3.19e-05	0.000229	CcSEcCtD
Mesalazine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	3.19e-05	0.000229	CcSEcCtD
Mesalazine—Pain—Irbesartan—type 2 diabetes mellitus	3.18e-05	0.000228	CcSEcCtD
Mesalazine—Constipation—Irbesartan—type 2 diabetes mellitus	3.18e-05	0.000228	CcSEcCtD
Mesalazine—Insomnia—Losartan—type 2 diabetes mellitus	3.17e-05	0.000227	CcSEcCtD
Mesalazine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	3.15e-05	0.000226	CcSEcCtD
Mesalazine—Paraesthesia—Losartan—type 2 diabetes mellitus	3.14e-05	0.000226	CcSEcCtD
Mesalazine—Urticaria—Metformin—type 2 diabetes mellitus	3.13e-05	0.000225	CcSEcCtD
Mesalazine—Arthralgia—Ramipril—type 2 diabetes mellitus	3.13e-05	0.000225	CcSEcCtD
Mesalazine—Chest pain—Ramipril—type 2 diabetes mellitus	3.13e-05	0.000225	CcSEcCtD
Mesalazine—Myalgia—Ramipril—type 2 diabetes mellitus	3.13e-05	0.000225	CcSEcCtD
Mesalazine—Dyspnoea—Losartan—type 2 diabetes mellitus	3.12e-05	0.000224	CcSEcCtD
Mesalazine—Anxiety—Ramipril—type 2 diabetes mellitus	3.12e-05	0.000224	CcSEcCtD
Mesalazine—Nausea—Glyburide—type 2 diabetes mellitus	3.12e-05	0.000224	CcSEcCtD
Mesalazine—Abdominal pain—Metformin—type 2 diabetes mellitus	3.12e-05	0.000224	CcSEcCtD
Mesalazine—Dizziness—Gliclazide—type 2 diabetes mellitus	3.12e-05	0.000224	CcSEcCtD
Mesalazine—Somnolence—Losartan—type 2 diabetes mellitus	3.11e-05	0.000223	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	3.11e-05	0.000223	CcSEcCtD
Mesalazine—Asthenia—Valsartan—type 2 diabetes mellitus	3.11e-05	0.000223	CcSEcCtD
Mesalazine—Discomfort—Ramipril—type 2 diabetes mellitus	3.09e-05	0.000222	CcSEcCtD
Mesalazine—Dyspepsia—Losartan—type 2 diabetes mellitus	3.08e-05	0.000221	CcSEcCtD
Mesalazine—Asthenia—Orlistat—type 2 diabetes mellitus	3.07e-05	0.00022	CcSEcCtD
Mesalazine—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	3.07e-05	0.00022	CcSEcCtD
Mesalazine—Pruritus—Valsartan—type 2 diabetes mellitus	3.06e-05	0.00022	CcSEcCtD
Mesalazine—Dry mouth—Ramipril—type 2 diabetes mellitus	3.06e-05	0.00022	CcSEcCtD
Mesalazine—Decreased appetite—Losartan—type 2 diabetes mellitus	3.04e-05	0.000218	CcSEcCtD
Mesalazine—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	3.04e-05	0.000218	CcSEcCtD
Mesalazine—Confusional state—Ramipril—type 2 diabetes mellitus	3.03e-05	0.000217	CcSEcCtD
Mesalazine—Pruritus—Orlistat—type 2 diabetes mellitus	3.03e-05	0.000217	CcSEcCtD
Mesalazine—Fatigue—Losartan—type 2 diabetes mellitus	3.02e-05	0.000217	CcSEcCtD
Mesalazine—Oedema—Ramipril—type 2 diabetes mellitus	3e-05	0.000216	CcSEcCtD
Mesalazine—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	3e-05	0.000216	CcSEcCtD
Mesalazine—Vomiting—Gliclazide—type 2 diabetes mellitus	3e-05	0.000215	CcSEcCtD
Mesalazine—Pain—Losartan—type 2 diabetes mellitus	2.99e-05	0.000215	CcSEcCtD
Mesalazine—Constipation—Losartan—type 2 diabetes mellitus	2.99e-05	0.000215	CcSEcCtD
Mesalazine—Rash—Gliclazide—type 2 diabetes mellitus	2.97e-05	0.000213	CcSEcCtD
Mesalazine—Dermatitis—Gliclazide—type 2 diabetes mellitus	2.97e-05	0.000213	CcSEcCtD
Mesalazine—Diarrhoea—Valsartan—type 2 diabetes mellitus	2.96e-05	0.000213	CcSEcCtD
Mesalazine—Urticaria—Irbesartan—type 2 diabetes mellitus	2.96e-05	0.000212	CcSEcCtD
Mesalazine—Shock—Ramipril—type 2 diabetes mellitus	2.95e-05	0.000212	CcSEcCtD
Mesalazine—Headache—Gliclazide—type 2 diabetes mellitus	2.95e-05	0.000212	CcSEcCtD
Mesalazine—Nervous system disorder—Ramipril—type 2 diabetes mellitus	2.94e-05	0.000211	CcSEcCtD
Mesalazine—Abdominal pain—Irbesartan—type 2 diabetes mellitus	2.94e-05	0.000211	CcSEcCtD
Mesalazine—Body temperature increased—Irbesartan—type 2 diabetes mellitus	2.94e-05	0.000211	CcSEcCtD
Mesalazine—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	2.94e-05	0.000211	CcSEcCtD
Mesalazine—Tachycardia—Ramipril—type 2 diabetes mellitus	2.93e-05	0.00021	CcSEcCtD
Mesalazine—Diarrhoea—Orlistat—type 2 diabetes mellitus	2.93e-05	0.00021	CcSEcCtD
Mesalazine—Skin disorder—Ramipril—type 2 diabetes mellitus	2.92e-05	0.000209	CcSEcCtD
Mesalazine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	2.9e-05	0.000208	CcSEcCtD
Mesalazine—Feeling abnormal—Losartan—type 2 diabetes mellitus	2.89e-05	0.000207	CcSEcCtD
Mesalazine—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	2.86e-05	0.000206	CcSEcCtD
Mesalazine—Dizziness—Valsartan—type 2 diabetes mellitus	2.86e-05	0.000206	CcSEcCtD
Mesalazine—Anorexia—Ramipril—type 2 diabetes mellitus	2.86e-05	0.000205	CcSEcCtD
Mesalazine—Dizziness—Orlistat—type 2 diabetes mellitus	2.83e-05	0.000203	CcSEcCtD
Mesalazine—Asthenia—Metformin—type 2 diabetes mellitus	2.83e-05	0.000203	CcSEcCtD
Mesalazine—Hypotension—Ramipril—type 2 diabetes mellitus	2.81e-05	0.000201	CcSEcCtD
Mesalazine—Nausea—Gliclazide—type 2 diabetes mellitus	2.8e-05	0.000201	CcSEcCtD
Mesalazine—Pruritus—Metformin—type 2 diabetes mellitus	2.79e-05	0.0002	CcSEcCtD
Mesalazine—Urticaria—Losartan—type 2 diabetes mellitus	2.78e-05	0.0002	CcSEcCtD
Mesalazine—Body temperature increased—Losartan—type 2 diabetes mellitus	2.77e-05	0.000199	CcSEcCtD
Mesalazine—Abdominal pain—Losartan—type 2 diabetes mellitus	2.77e-05	0.000199	CcSEcCtD
Mesalazine—Vomiting—Valsartan—type 2 diabetes mellitus	2.75e-05	0.000198	CcSEcCtD
Mesalazine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	2.74e-05	0.000197	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	2.74e-05	0.000196	CcSEcCtD
Mesalazine—Rash—Valsartan—type 2 diabetes mellitus	2.73e-05	0.000196	CcSEcCtD
Mesalazine—Dermatitis—Valsartan—type 2 diabetes mellitus	2.73e-05	0.000196	CcSEcCtD
Mesalazine—Vomiting—Orlistat—type 2 diabetes mellitus	2.72e-05	0.000195	CcSEcCtD
Mesalazine—Insomnia—Ramipril—type 2 diabetes mellitus	2.72e-05	0.000195	CcSEcCtD
Mesalazine—Headache—Valsartan—type 2 diabetes mellitus	2.71e-05	0.000195	CcSEcCtD
Mesalazine—Diarrhoea—Metformin—type 2 diabetes mellitus	2.7e-05	0.000194	CcSEcCtD
Mesalazine—Rash—Orlistat—type 2 diabetes mellitus	2.7e-05	0.000194	CcSEcCtD
Mesalazine—Paraesthesia—Ramipril—type 2 diabetes mellitus	2.7e-05	0.000194	CcSEcCtD
Mesalazine—Dermatitis—Orlistat—type 2 diabetes mellitus	2.69e-05	0.000193	CcSEcCtD
Mesalazine—Headache—Orlistat—type 2 diabetes mellitus	2.68e-05	0.000192	CcSEcCtD
Mesalazine—Dyspnoea—Ramipril—type 2 diabetes mellitus	2.68e-05	0.000192	CcSEcCtD
Mesalazine—Asthenia—Irbesartan—type 2 diabetes mellitus	2.67e-05	0.000192	CcSEcCtD
Mesalazine—Somnolence—Ramipril—type 2 diabetes mellitus	2.67e-05	0.000192	CcSEcCtD
Mesalazine—Dyspepsia—Ramipril—type 2 diabetes mellitus	2.64e-05	0.00019	CcSEcCtD
Mesalazine—Pruritus—Irbesartan—type 2 diabetes mellitus	2.63e-05	0.000189	CcSEcCtD
Mesalazine—Decreased appetite—Ramipril—type 2 diabetes mellitus	2.61e-05	0.000187	CcSEcCtD
Mesalazine—Dizziness—Metformin—type 2 diabetes mellitus	2.61e-05	0.000187	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	2.59e-05	0.000186	CcSEcCtD
Mesalazine—Fatigue—Ramipril—type 2 diabetes mellitus	2.59e-05	0.000186	CcSEcCtD
Mesalazine—Hypersensitivity—Losartan—type 2 diabetes mellitus	2.58e-05	0.000185	CcSEcCtD
Mesalazine—Nausea—Valsartan—type 2 diabetes mellitus	2.57e-05	0.000185	CcSEcCtD
Mesalazine—Constipation—Ramipril—type 2 diabetes mellitus	2.57e-05	0.000184	CcSEcCtD
Mesalazine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	2.55e-05	0.000183	CcSEcCtD
Mesalazine—Nausea—Orlistat—type 2 diabetes mellitus	2.54e-05	0.000182	CcSEcCtD
Mesalazine—Asthenia—Losartan—type 2 diabetes mellitus	2.51e-05	0.00018	CcSEcCtD
Mesalazine—Vomiting—Metformin—type 2 diabetes mellitus	2.51e-05	0.00018	CcSEcCtD
Mesalazine—Rash—Metformin—type 2 diabetes mellitus	2.49e-05	0.000178	CcSEcCtD
Mesalazine—Dermatitis—Metformin—type 2 diabetes mellitus	2.48e-05	0.000178	CcSEcCtD
Mesalazine—Pruritus—Losartan—type 2 diabetes mellitus	2.48e-05	0.000178	CcSEcCtD
Mesalazine—Feeling abnormal—Ramipril—type 2 diabetes mellitus	2.47e-05	0.000178	CcSEcCtD
Mesalazine—Headache—Metformin—type 2 diabetes mellitus	2.47e-05	0.000177	CcSEcCtD
Mesalazine—Dizziness—Irbesartan—type 2 diabetes mellitus	2.46e-05	0.000177	CcSEcCtD
Mesalazine—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	2.46e-05	0.000176	CcSEcCtD
Mesalazine—Diarrhoea—Losartan—type 2 diabetes mellitus	2.4e-05	0.000172	CcSEcCtD
Mesalazine—Urticaria—Ramipril—type 2 diabetes mellitus	2.39e-05	0.000171	CcSEcCtD
Mesalazine—Abdominal pain—Ramipril—type 2 diabetes mellitus	2.37e-05	0.00017	CcSEcCtD
Mesalazine—Body temperature increased—Ramipril—type 2 diabetes mellitus	2.37e-05	0.00017	CcSEcCtD
Mesalazine—Vomiting—Irbesartan—type 2 diabetes mellitus	2.37e-05	0.00017	CcSEcCtD
Mesalazine—Rash—Irbesartan—type 2 diabetes mellitus	2.35e-05	0.000168	CcSEcCtD
Mesalazine—Dermatitis—Irbesartan—type 2 diabetes mellitus	2.34e-05	0.000168	CcSEcCtD
Mesalazine—Nausea—Metformin—type 2 diabetes mellitus	2.34e-05	0.000168	CcSEcCtD
Mesalazine—Headache—Irbesartan—type 2 diabetes mellitus	2.33e-05	0.000167	CcSEcCtD
Mesalazine—Dizziness—Losartan—type 2 diabetes mellitus	2.32e-05	0.000166	CcSEcCtD
Mesalazine—Vomiting—Losartan—type 2 diabetes mellitus	2.23e-05	0.00016	CcSEcCtD
Mesalazine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	2.21e-05	0.000159	CcSEcCtD
Mesalazine—Nausea—Irbesartan—type 2 diabetes mellitus	2.21e-05	0.000159	CcSEcCtD
Mesalazine—Rash—Losartan—type 2 diabetes mellitus	2.21e-05	0.000158	CcSEcCtD
Mesalazine—Dermatitis—Losartan—type 2 diabetes mellitus	2.21e-05	0.000158	CcSEcCtD
Mesalazine—Headache—Losartan—type 2 diabetes mellitus	2.19e-05	0.000157	CcSEcCtD
Mesalazine—Asthenia—Ramipril—type 2 diabetes mellitus	2.15e-05	0.000155	CcSEcCtD
Mesalazine—Pruritus—Ramipril—type 2 diabetes mellitus	2.12e-05	0.000152	CcSEcCtD
Mesalazine—Nausea—Losartan—type 2 diabetes mellitus	2.08e-05	0.000149	CcSEcCtD
Mesalazine—Diarrhoea—Ramipril—type 2 diabetes mellitus	2.05e-05	0.000147	CcSEcCtD
Mesalazine—Dizziness—Ramipril—type 2 diabetes mellitus	1.99e-05	0.000143	CcSEcCtD
Mesalazine—Vomiting—Ramipril—type 2 diabetes mellitus	1.91e-05	0.000137	CcSEcCtD
Mesalazine—Rash—Ramipril—type 2 diabetes mellitus	1.89e-05	0.000136	CcSEcCtD
Mesalazine—Dermatitis—Ramipril—type 2 diabetes mellitus	1.89e-05	0.000136	CcSEcCtD
Mesalazine—Headache—Ramipril—type 2 diabetes mellitus	1.88e-05	0.000135	CcSEcCtD
Mesalazine—Nausea—Ramipril—type 2 diabetes mellitus	1.78e-05	0.000128	CcSEcCtD
Mesalazine—PTGS2—Metabolism—HBA1—type 2 diabetes mellitus	4.81e-06	5.17e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP3A4—type 2 diabetes mellitus	4.79e-06	5.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IRS1—type 2 diabetes mellitus	4.79e-06	5.15e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GCG—type 2 diabetes mellitus	4.79e-06	5.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTPN1—type 2 diabetes mellitus	4.79e-06	5.14e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP11A1—type 2 diabetes mellitus	4.78e-06	5.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—NFKB1—type 2 diabetes mellitus	4.78e-06	5.13e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	4.77e-06	5.12e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—MTHFR—type 2 diabetes mellitus	4.75e-06	5.11e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—SLC2A4—type 2 diabetes mellitus	4.71e-06	5.06e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GCG—type 2 diabetes mellitus	4.71e-06	5.06e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	4.71e-06	5.06e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	4.7e-06	5.05e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SLC9A1—type 2 diabetes mellitus	4.7e-06	5.04e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PPARA—type 2 diabetes mellitus	4.66e-06	5.01e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SLC2A1—type 2 diabetes mellitus	4.66e-06	5.01e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CETP—type 2 diabetes mellitus	4.64e-06	4.99e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—SRC—type 2 diabetes mellitus	4.64e-06	4.98e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOS2—type 2 diabetes mellitus	4.62e-06	4.97e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	4.6e-06	4.94e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PRKCB—type 2 diabetes mellitus	4.6e-06	4.94e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS1—type 2 diabetes mellitus	4.59e-06	4.93e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ICAM1—type 2 diabetes mellitus	4.58e-06	4.92e-05	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	4.56e-06	4.9e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—GNB3—type 2 diabetes mellitus	4.55e-06	4.89e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TCF7L2—type 2 diabetes mellitus	4.54e-06	4.88e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AGT—type 2 diabetes mellitus	4.52e-06	4.85e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CASP8—type 2 diabetes mellitus	4.52e-06	4.85e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AVP—type 2 diabetes mellitus	4.49e-06	4.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP3—type 2 diabetes mellitus	4.49e-06	4.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EGFR—type 2 diabetes mellitus	4.48e-06	4.81e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF2—type 2 diabetes mellitus	4.47e-06	4.8e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SLC2A4—type 2 diabetes mellitus	4.47e-06	4.8e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—SERPINE1—type 2 diabetes mellitus	4.47e-06	4.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	4.45e-06	4.78e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—SRC—type 2 diabetes mellitus	4.45e-06	4.78e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CALM1—type 2 diabetes mellitus	4.44e-06	4.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT2—type 2 diabetes mellitus	4.44e-06	4.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IRS1—type 2 diabetes mellitus	4.43e-06	4.75e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—APOE—type 2 diabetes mellitus	4.43e-06	4.75e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—APOA1—type 2 diabetes mellitus	4.38e-06	4.7e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IRS1—type 2 diabetes mellitus	4.35e-06	4.67e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOB—type 2 diabetes mellitus	4.34e-06	4.66e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	4.33e-06	4.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1R—type 2 diabetes mellitus	4.32e-06	4.64e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SREBF1—type 2 diabetes mellitus	4.32e-06	4.64e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SNAP25—type 2 diabetes mellitus	4.32e-06	4.64e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PSMD6—type 2 diabetes mellitus	4.32e-06	4.64e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—EGFR—type 2 diabetes mellitus	4.3e-06	4.62e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EDN1—type 2 diabetes mellitus	4.27e-06	4.59e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—INS—type 2 diabetes mellitus	4.24e-06	4.55e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CTGF—type 2 diabetes mellitus	4.24e-06	4.55e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HMGCR—type 2 diabetes mellitus	4.2e-06	4.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	4.17e-06	4.48e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—IL6—type 2 diabetes mellitus	4.15e-06	4.46e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—LPL—type 2 diabetes mellitus	4.14e-06	4.45e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	4.14e-06	4.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GNB3—type 2 diabetes mellitus	4.13e-06	4.43e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ADRA2A—type 2 diabetes mellitus	4.11e-06	4.41e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT2—type 2 diabetes mellitus	4.1e-06	4.4e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CASP8—type 2 diabetes mellitus	4.1e-06	4.4e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AVP—type 2 diabetes mellitus	4.07e-06	4.37e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP3—type 2 diabetes mellitus	4.07e-06	4.37e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EGFR—type 2 diabetes mellitus	4.06e-06	4.36e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GNB3—type 2 diabetes mellitus	4.06e-06	4.36e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.06e-06	4.36e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.06e-06	4.36e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF2—type 2 diabetes mellitus	4.05e-06	4.36e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—HMOX1—type 2 diabetes mellitus	4.04e-06	4.34e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	4.04e-06	4.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3R1—type 2 diabetes mellitus	4.03e-06	4.32e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT2—type 2 diabetes mellitus	4.02e-06	4.32e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CAT—type 2 diabetes mellitus	3.99e-06	4.29e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP2E1—type 2 diabetes mellitus	3.95e-06	4.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOB—type 2 diabetes mellitus	3.94e-06	4.23e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1R—type 2 diabetes mellitus	3.92e-06	4.21e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SLC2A1—type 2 diabetes mellitus	3.9e-06	4.19e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP1A2—type 2 diabetes mellitus	3.9e-06	4.19e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—EGFR—type 2 diabetes mellitus	3.9e-06	4.19e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—SERPINE1—type 2 diabetes mellitus	3.89e-06	4.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	3.89e-06	4.18e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TGFBR2—type 2 diabetes mellitus	3.89e-06	4.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—BCL2—type 2 diabetes mellitus	3.88e-06	4.16e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOB—type 2 diabetes mellitus	3.87e-06	4.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EDN1—type 2 diabetes mellitus	3.87e-06	4.16e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—AKT1—type 2 diabetes mellitus	3.83e-06	4.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.82e-06	4.1e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP3A4—type 2 diabetes mellitus	3.81e-06	4.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—RELA—type 2 diabetes mellitus	3.79e-06	4.07e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—INS—type 2 diabetes mellitus	3.78e-06	4.06e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTM1—type 2 diabetes mellitus	3.77e-06	4.05e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN2B—type 2 diabetes mellitus	3.77e-06	4.05e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—LPL—type 2 diabetes mellitus	3.76e-06	4.04e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SLC2A4—type 2 diabetes mellitus	3.74e-06	4.02e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GCG—type 2 diabetes mellitus	3.74e-06	4.02e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—C3—type 2 diabetes mellitus	3.73e-06	4.01e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3R1—type 2 diabetes mellitus	3.72e-06	3.99e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOS3—type 2 diabetes mellitus	3.72e-06	3.99e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—LPL—type 2 diabetes mellitus	3.7e-06	3.97e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ADCY5—type 2 diabetes mellitus	3.68e-06	3.95e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOB—type 2 diabetes mellitus	3.67e-06	3.94e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3R1—type 2 diabetes mellitus	3.65e-06	3.92e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ADCY5—type 2 diabetes mellitus	3.62e-06	3.89e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GPX1—type 2 diabetes mellitus	3.61e-06	3.88e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.56e-06	3.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.55e-06	3.81e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AGT—type 2 diabetes mellitus	3.55e-06	3.81e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	3.53e-06	3.79e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—BCL2—type 2 diabetes mellitus	3.51e-06	3.78e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CD36—type 2 diabetes mellitus	3.51e-06	3.77e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—LPL—type 2 diabetes mellitus	3.51e-06	3.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.49e-06	3.75e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—LEP—type 2 diabetes mellitus	3.47e-06	3.73e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOE—type 2 diabetes mellitus	3.47e-06	3.73e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPP2CA—type 2 diabetes mellitus	3.47e-06	3.73e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ALB—type 2 diabetes mellitus	3.47e-06	3.72e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.46e-06	3.72e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—type 2 diabetes mellitus	3.44e-06	3.7e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—RELA—type 2 diabetes mellitus	3.44e-06	3.69e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.43e-06	3.69e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ADCY5—type 2 diabetes mellitus	3.43e-06	3.69e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—type 2 diabetes mellitus	3.4e-06	3.65e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—C3—type 2 diabetes mellitus	3.38e-06	3.63e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—MTHFR—type 2 diabetes mellitus	3.33e-06	3.58e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3R1—type 2 diabetes mellitus	3.32e-06	3.56e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—NOS3—type 2 diabetes mellitus	3.32e-06	3.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PPP2CA—type 2 diabetes mellitus	3.29e-06	3.53e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.28e-06	3.52e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARA—type 2 diabetes mellitus	3.27e-06	3.51e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CCR5—type 2 diabetes mellitus	3.23e-06	3.47e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.23e-06	3.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.23e-06	3.46e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GNB3—type 2 diabetes mellitus	3.23e-06	3.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.22e-06	3.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AGT—type 2 diabetes mellitus	3.22e-06	3.45e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HMOX1—type 2 diabetes mellitus	3.21e-06	3.45e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NFKB1—type 2 diabetes mellitus	3.2e-06	3.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—type 2 diabetes mellitus	3.18e-06	3.41e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CAT—type 2 diabetes mellitus	3.17e-06	3.4e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AGT—type 2 diabetes mellitus	3.16e-06	3.4e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.16e-06	3.4e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTHFR—type 2 diabetes mellitus	3.16e-06	3.39e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—LEP—type 2 diabetes mellitus	3.15e-06	3.38e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOE—type 2 diabetes mellitus	3.15e-06	3.38e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—type 2 diabetes mellitus	3.12e-06	3.35e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.11e-06	3.35e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CALM1—type 2 diabetes mellitus	3.11e-06	3.34e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOE—type 2 diabetes mellitus	3.1e-06	3.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.1e-06	3.33e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOB—type 2 diabetes mellitus	3.08e-06	3.3e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOA1—type 2 diabetes mellitus	3.06e-06	3.29e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—type 2 diabetes mellitus	3.05e-06	3.28e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—type 2 diabetes mellitus	3.03e-06	3.26e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HIF1A—type 2 diabetes mellitus	3.01e-06	3.23e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IRS2—type 2 diabetes mellitus	3e-06	3.23e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTM1—type 2 diabetes mellitus	2.99e-06	3.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—SRC—type 2 diabetes mellitus	2.98e-06	3.2e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.97e-06	3.19e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—INS—type 2 diabetes mellitus	2.97e-06	3.19e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CALM1—type 2 diabetes mellitus	2.95e-06	3.17e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOE—type 2 diabetes mellitus	2.94e-06	3.16e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—LPL—type 2 diabetes mellitus	2.94e-06	3.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.92e-06	3.14e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOA1—type 2 diabetes mellitus	2.91e-06	3.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NFKB1—type 2 diabetes mellitus	2.9e-06	3.11e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—type 2 diabetes mellitus	2.88e-06	3.09e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ADCY5—type 2 diabetes mellitus	2.87e-06	3.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.87e-06	3.08e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.87e-06	3.08e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GPX1—type 2 diabetes mellitus	2.86e-06	3.08e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.81e-06	3.02e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CD36—type 2 diabetes mellitus	2.79e-06	3e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—type 2 diabetes mellitus	2.77e-06	2.97e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPP2CA—type 2 diabetes mellitus	2.75e-06	2.96e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—SRC—type 2 diabetes mellitus	2.75e-06	2.95e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS2—type 2 diabetes mellitus	2.74e-06	2.94e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.73e-06	2.93e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARG—type 2 diabetes mellitus	2.7e-06	2.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—SRC—type 2 diabetes mellitus	2.7e-06	2.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—INS—type 2 diabetes mellitus	2.69e-06	2.89e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—INS—type 2 diabetes mellitus	2.65e-06	2.84e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.65e-06	2.84e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—MTHFR—type 2 diabetes mellitus	2.64e-06	2.84e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IRS1—type 2 diabetes mellitus	2.62e-06	2.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—type 2 diabetes mellitus	2.61e-06	2.8e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.6e-06	2.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.6e-06	2.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.6e-06	2.8e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.6e-06	2.79e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARA—type 2 diabetes mellitus	2.59e-06	2.79e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AGT—type 2 diabetes mellitus	2.51e-06	2.7e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—INS—type 2 diabetes mellitus	2.51e-06	2.7e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.47e-06	2.66e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CALM1—type 2 diabetes mellitus	2.47e-06	2.65e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—type 2 diabetes mellitus	2.46e-06	2.64e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOE—type 2 diabetes mellitus	2.46e-06	2.64e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—TGFB1—type 2 diabetes mellitus	2.46e-06	2.64e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RELA—type 2 diabetes mellitus	2.45e-06	2.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOA1—type 2 diabetes mellitus	2.43e-06	2.61e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ALB—type 2 diabetes mellitus	2.43e-06	2.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT2—type 2 diabetes mellitus	2.43e-06	2.61e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—type 2 diabetes mellitus	2.41e-06	2.59e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—type 2 diabetes mellitus	2.37e-06	2.54e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.36e-06	2.54e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.36e-06	2.54e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NOS3—type 2 diabetes mellitus	2.32e-06	2.49e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3R1—type 2 diabetes mellitus	2.32e-06	2.49e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SERPINE1—type 2 diabetes mellitus	2.31e-06	2.48e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RELA—type 2 diabetes mellitus	2.22e-06	2.39e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.21e-06	2.37e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3R1—type 2 diabetes mellitus	2.2e-06	2.36e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS3—type 2 diabetes mellitus	2.2e-06	2.36e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARG—type 2 diabetes mellitus	2.14e-06	2.3e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—type 2 diabetes mellitus	2.12e-06	2.28e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—INS—type 2 diabetes mellitus	2.1e-06	2.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.09e-06	2.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.07e-06	2.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—type 2 diabetes mellitus	2.01e-06	2.15e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CASP3—type 2 diabetes mellitus	2e-06	2.15e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—type 2 diabetes mellitus	1.96e-06	2.11e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ALB—type 2 diabetes mellitus	1.93e-06	2.07e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SRC—type 2 diabetes mellitus	1.93e-06	2.07e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.89e-06	2.03e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.88e-06	2.01e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.87e-06	2.01e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—type 2 diabetes mellitus	1.85e-06	1.99e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—type 2 diabetes mellitus	1.85e-06	1.99e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.84e-06	1.98e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NOS3—type 2 diabetes mellitus	1.84e-06	1.98e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—type 2 diabetes mellitus	1.82e-06	1.95e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SRC—type 2 diabetes mellitus	1.75e-06	1.88e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.72e-06	1.85e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—type 2 diabetes mellitus	1.71e-06	1.84e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.7e-06	1.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.69e-06	1.81e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—type 2 diabetes mellitus	1.68e-06	1.8e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SRC—type 2 diabetes mellitus	1.63e-06	1.75e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.56e-06	1.68e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.53e-06	1.64e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—type 2 diabetes mellitus	1.52e-06	1.64e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TGFB1—type 2 diabetes mellitus	1.46e-06	1.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—type 2 diabetes mellitus	1.43e-06	1.53e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—type 2 diabetes mellitus	1.3e-06	1.39e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.2e-06	1.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—type 2 diabetes mellitus	1.18e-06	1.26e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—type 2 diabetes mellitus	1.1e-06	1.18e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.08e-06	1.17e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—type 2 diabetes mellitus	1.07e-06	1.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—type 2 diabetes mellitus	1.01e-06	1.09e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—type 2 diabetes mellitus	8.48e-07	9.1e-06	CbGpPWpGaD
